Literature DB >> 4700488

Mechanisms of immune lysis of red blood cells in vitro. I. Paroxysmal nocturnal hemoglobinuria cells.

G L Logue, W F Rosse, J P Adams.   

Abstract

The effect of five different reactions which activate complement (antibody activation, reduction in ionic strength, acidification, cobra venom factor (CoF) activation, and inulin activation) upon normal and PNH cells was investigated, using normal serum and serum devoid of the fourth component of complement (C4) activity from patients with hereditary angioneurotic edema (HANE) as a source of complement. Both normal and HANE serum lysed paroxysmal nocturnal hemoglobinuria (PNH) cells when complement was activated by acidification, CoF and inulin, indicating that the terminal steps of complement were activated in the absence of C4, presumably by the alternate or properdin pathway. Normal but not HANE serum lysed cells coated with anti-I, indicating that complement was activated by the C1-dependent classic pathway. HANE serum partially supported lysis by serum at reduced ionic strength, indicating that the activation of terminal complement components had occurred through both of the pathways of activation. The amount of the third component of human complement (C3) which was bound to the membrane of lysed and unlysed cells by these procedures was determined by anti-C3 absorption and was found to differ for each method of complement activation. In general, more C3 was bound to lysed cells than to unlysed cells. For given conditions, more was bound to PNH cells than to normal cells. However, very much less bound C3 was required for lysis of the PNH cells than for lysis of normal cells. These two phenomena, especially the latter, account for the marked lysis of PNH cells when complement is activated. Normal cells treated with AET (aminoethylisothiouronium bromide) did not bind more C3 than untreated cells and the lysed cells had less bound C3 than lysed PNH cells.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4700488      PMCID: PMC302368          DOI: 10.1172/JCI107279

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  20 in total

1.  ACTION OF COMPLEMENT IN HEREDITARY ANGIONEUROTIC EDEMA: THE ROLE OF C'1-ESTERASE.

Authors:  V H DONALDSON; F S ROSEN
Journal:  J Clin Invest       Date:  1964-11       Impact factor: 14.808

2.  pH dependent hemolytic systems. II. Serum factors involved in red cell lysis.

Authors:  S YACHNIN; F H GARDNER
Journal:  Blood       Date:  1961-04       Impact factor: 22.113

3.  The properdin system and immunity. IV. The hemolysis of erythrocytes from patients with paroxysmal nocturnal hemoglobinuria.

Authors:  C F HINZ; W S JORDAN; L PILLEMER
Journal:  J Clin Invest       Date:  1956-05       Impact factor: 14.808

4.  The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena.

Authors:  L PILLEMER; L BLUM; I H LEPOW; O A ROSS; E W TODD; A C WARDLAW
Journal:  Science       Date:  1954-08-20       Impact factor: 47.728

5.  STUDIES ON DESTRUCTION OF RED BLOOD CELLS. II. CHRONIC HEMOLYTIC ANEMIA WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: CERTAIN IMMUNOLOGICAL ASPECTS OF THE HEMOLYTIC MECHANISM WITH SPECIAL REFERENCE TO SERUM COMPLEMENT.

Authors:  T H Ham; J H Dingle
Journal:  J Clin Invest       Date:  1939-11       Impact factor: 14.808

6.  Cobra venom factor-induced activation of the complement system: developmental, experimental and clinical considerations.

Authors:  H Gewurz; R J Pickering; N K Day; R A Good
Journal:  Int Arch Allergy Appl Immunol       Date:  1971

7.  Detection of bound C3 by a new immunochemical methods.

Authors:  T Borsos; E J Leonard
Journal:  J Immunol       Date:  1971-09       Impact factor: 5.422

8.  Erythrocyte acetylcholinesterase deficiency in paroxysmal nocturnal hemoglobinuria (PNH). A comparison of the complement-sensitive and insensitive populations.

Authors:  T R Kunstling; W F Rosse
Journal:  Blood       Date:  1969-04       Impact factor: 22.113

9.  Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. I. The sensitivity of PNH red cells to lysis by complement and specific antibody.

Authors:  W F Rosse; J V Dacie
Journal:  J Clin Invest       Date:  1966-05       Impact factor: 14.808

10.  Immune lysis of AET-treated normal red cells (PNH-like cells).

Authors:  G Sirchia; J V Dacie
Journal:  Nature       Date:  1967-08-12       Impact factor: 49.962

View more
  23 in total

Review 1.  Paroxysmal nocturnal hemoglobinuria and glycosyl phosphatidylinositol anchored proteins that regulate complement.

Authors:  C J Parker
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

2.  Human lymphocyte complement receptors. Quantitative requirements for C3 of normal and chronic lymphocyte leukemia lymphocytes.

Authors:  G L Logue; H J Cohen
Journal:  J Clin Invest       Date:  1977-11       Impact factor: 14.808

Review 3.  [Paroxysmal nocturnal hemoglobinuria].

Authors:  P Blaas; S Weber; G M Hänsch; H H Peter
Journal:  Klin Wochenschr       Date:  1990-03-05

4.  Mechanisms of immune lysis of the red cells in hereditary erythroblastic multinuclearity with a positive acidified serum test and paroxysmal nocturnal hemoglobinuria.

Authors:  W F Rosse; G L Logue; J Adams; J H Crookston
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

5.  Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.

Authors:  Anita Hill; Russell P Rother; Louise Arnold; Richard Kelly; Matthew J Cullen; Stephen J Richards; Peter Hillmen
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

6.  Mechanism of complement-mediated activation of human blood platelets in vitro: comparison of normal and paroxysmal nocturnal hemoglobinuria platelets.

Authors:  R H Dixon; W F Rosse
Journal:  J Clin Invest       Date:  1977-02       Impact factor: 14.808

Review 7.  The alternative pathway of complement.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Springer Semin Immunopathol       Date:  1984

8.  Studies on the inhibition of C56-initiated lysis (reactive lysis). V. The roleof C567-INH in the regulation of complement-dependent haemolysis initiated by cobravenom factor.

Authors:  B McLeod; T F Lint; P Baker; C Behrends; H Gewurz
Journal:  Immunology       Date:  1975-04       Impact factor: 7.397

9.  Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9.

Authors:  C H Packman; S I Rosenfeld; D E Jenkins; P A Thiem; J P Leddy
Journal:  J Clin Invest       Date:  1979-08       Impact factor: 14.808

10.  Paroxysmal nocturnal hemoglobinuria type III. Lack of an erythrocyte membrane protein restricting the lysis by C5b-9.

Authors:  G M Hänsch; S Schönermark; D Roelcke
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.